Figure legends
FIGURE 1 CD19 CAR T cells are highly effective against MPAL patients.
(A) CAR T cell proliferation and persistence. Percentages of CD19 CAR T
cells in peripheral blood were measured by flow cytometry before and
after infusion. (B) FDG uptake in neck infiltrating loci disappeared
after CAR T therapy. (C) Leukemia blasts in bone marrow aspirate before
and post infusion were measured by Wright-Giemsa staining. (D) Cytokine
levels in peripheral blood of patients were measured by ELISA assay at
indicated time points after infusion.